The Splicing Factor CELF4 Is Dysregulated in Neuroendocrine Tumors, Where It Can Enhance Aggressiveness Features
Introduction: There is increasing evidence that alterations in alternative splicing are linked to key tumor features in different cancers. Besides mutations, dysregulation of the splicing machinery would represent the main underlying cause for these alterations. Indeed, splicing dysregulation is emerging as a novel, transversal cancer hallmark, due to its association with multiple dysfunctions in tumor cells.
Aim(s): Here, we evaluate the (dys)regulation and functional role of the splicing factor CELF4 in neuroendocrine tumors (NETs), particularly focusing in pancreatic NETs (PanNETs).
Materials and methods: CELF4 expression levels were determined by qPCR in 20 PanNETs, and in 256 pituitary tumors (PitNETs), and their corresponding control tissues. Additionally, model cell lines, BON-1 and QGP-1, were used to explore CELF4 function in PanNETs.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Alors-Pérez E
To read the full abstract, please log into your ENETS Member account.